基本信息
浏览量:197
职业迁徙
个人简介
Dr. Carracedo scientific career started and has always been related to a single question: What are the differences between normal and cancer cells that can allow us to develop more selective and effective therapies? During his undergraduate studies and later in his PhD thesis work, he approached this question by studying a family of compounds, cannabinoids, which show a high selectivity between normal and cancer cells. His work in the Guzman laboratory allowed them to uncover a novel signaling pathway that links cannabinoid receptor activation to endoplasmic reticulum stress-induced apoptosis, through a novel regulator, the stress protein p8. At the end of his period in Guzman laboratory, he had continued his work discovering that these compounds could regulate autophagy through the oncogenic PI3K-mTOR pathway, and in turn he became very interested in how this signaling pathway could influence cancer cell biology and the relevance of its pharmacological targeting in cancer. With this idea in mind, he joined Pier Paolo Pandolfi´s laboratory, at the time in Memorial Sloan Kettering Cancer Center, to continue his work from a different and innovative angle.
Dr. Carracedo joined the lab of Prof. Pandolfi with one idea in mind: to learn from a very different angle, and using different array of techniques, how the cancer cell functions and how can we target it for therapy. To this end, he focused these years in studying the regulation and relevance of the oncogenic PI3K-mTOR pathway in cancer. On the one hand, he has contributed to increase the knowledge of how the tumor suppressor PTEN operates and its relevance in prostate cancer cell biology. On the other hand, he has contributed to define the means of regulation of the mTOR signaling node and the therapeutic opportunities that modulating this kinase could offer. He addressed these questions, through the use of cell biology studies as well as employing genetically modified mouse models of human cancer. In the last phase of his post-doc, he became more interested in how another feature of cancer cells, the metabolic reprogramming, functions and how can it be used for therapy. In this line, he has developed studies focusing on the regulation of fatty acid oxidation in cancer cells, which are now submitted to publication. This has become one of his interests to build his independent line of research in his new position in the CIC bioGUNE institute in Bilbao, Spain, answering a key question: What is the contribution of cell metabolism to cancer cell biology and how can we use it for therapy? Currently, the Carracedo lab is composed of 9 people, including 3 postdocs, 2 PhD students, 1 bioinformatician and 3 technicians. This team of work contributes with very different perspectives, from stem cell work to nutrition, and therefore ensures that such a multidisciplinary proposal can be carried out.
Dr. Carracedo joined the lab of Prof. Pandolfi with one idea in mind: to learn from a very different angle, and using different array of techniques, how the cancer cell functions and how can we target it for therapy. To this end, he focused these years in studying the regulation and relevance of the oncogenic PI3K-mTOR pathway in cancer. On the one hand, he has contributed to increase the knowledge of how the tumor suppressor PTEN operates and its relevance in prostate cancer cell biology. On the other hand, he has contributed to define the means of regulation of the mTOR signaling node and the therapeutic opportunities that modulating this kinase could offer. He addressed these questions, through the use of cell biology studies as well as employing genetically modified mouse models of human cancer. In the last phase of his post-doc, he became more interested in how another feature of cancer cells, the metabolic reprogramming, functions and how can it be used for therapy. In this line, he has developed studies focusing on the regulation of fatty acid oxidation in cancer cells, which are now submitted to publication. This has become one of his interests to build his independent line of research in his new position in the CIC bioGUNE institute in Bilbao, Spain, answering a key question: What is the contribution of cell metabolism to cancer cell biology and how can we use it for therapy? Currently, the Carracedo lab is composed of 9 people, including 3 postdocs, 2 PhD students, 1 bioinformatician and 3 technicians. This team of work contributes with very different perspectives, from stem cell work to nutrition, and therefore ensures that such a multidisciplinary proposal can be carried out.
研究兴趣
论文共 166 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Sandra Santasusagna,Shijia Zhu, Vijayakumar Jawalagatti,Marc Carceles-Cordon,Adam Ertel,Saioa Garcia-Longarte, Won-Min Song,Naoto Fujiwara,Peiyao Li,Isabel Mendizabal,Daniel P. Petrylak,William Kevin Kelly,
Molecular Oncologyno. 6 (2023): 921-924
引用0浏览0WOS引用
0
0
crossref(2023)
Molecular cancerno. 1 (2023): 1-25
Raquel García-Vílchez,Ana M. Añazco-Guenkova,Sabine Dietmann,Judith López, Virginia Morón-Calvente, Silvia D’Ambrosi,Paz Nombela, Kepa Zamacola,Isabel Mendizabal,Saioa García-Longarte,Amaia Zabala-Letona,Ianire Astobiza,
引用1浏览0WOS引用
1
0
Cristina Blázquez,María Salazar,Arkaitz Carracedo,Mar Lorente,Ainara Egia, Luis González-Feria,Amador Haro,Guillermo Velasco,Manuel Guzmán
crossref(2023)
Shawn M. Davidson,Daniel R. Schmidt, Julia E. Heyman, James P. O'Brien, Amy C. Liu,William J. Israelsen,Talya L. Dayton,Raghav Sehgal,Roderick T. Bronson,Elizaveta Freinkman, Howard H. Mak,Giuseppe Nicolò Fanelli,
crossref(2023)
crossref(2023)
Natalia Martín-Martín,Amaia Zabala-Letona,Sonia Fernández-Ruiz,Leire Arreal,Laura Camacho,Mireia Castillo-Martin,Ana R. Cortazar,Verónica Torrano,Ianire Astobiza,Patricia Zúñiga-García, Aitziber Ugalde-Olano,Ana Loizaga-Iriarte,
crossref(2023)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn